Core Viewpoint - New Oriental Education (EDU) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which in turn affects stock prices [4]. Company Performance and Outlook - For the fiscal year ending May 2026, New Oriental is expected to earn $3.73 per share, with a 5.6% increase in the Zacks Consensus Estimate over the past three months, reflecting a positive trend in earnings estimates [8]. - The upgrade to Zacks Rank 1 signifies an improvement in New Oriental's underlying business, which is likely to drive the stock price higher as investors respond to this trend [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988, indicating a strong track record for this rating [7]. - Only the top 5% of Zacks-covered stocks receive a "Strong Buy" rating, suggesting that New Oriental's position reflects its superior earnings estimate revision feature, making it a strong candidate for market-beating returns [9][10].

Core Viewpoint - New Oriental Education (EDU) is currently viewed as a more attractive investment compared to Universal Technical Institute (UTI) based on various valuation metrics and earnings outlook [1][3][6] Valuation Metrics - EDU has a forward P/E ratio of 15.15, significantly lower than UTI's forward P/E of 51.51, indicating that EDU may be undervalued [5] - The PEG ratio for EDU is 0.81, while UTI's PEG ratio is 3.43, suggesting that EDU offers better value when considering expected earnings growth [5] - EDU's P/B ratio stands at 2.12, compared to UTI's P/B of 6.5, further supporting the notion that EDU is a more favorable investment option [6] Analyst Outlook - EDU holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings estimate revision trend, while UTI has a Zacks Rank of 3 (Hold), reflecting a less favorable analyst outlook [3][6] - Based on the combination of valuation metrics and analyst ratings, EDU is positioned as the superior value option in the education sector [6]

Company Overview - New Oriental Education (EDU) is a notable stock within the Consumer Discretionary sector, which consists of 257 individual stocks [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions [3] Performance Analysis - Over the past three months, the Zacks Consensus Estimate for EDU's full-year earnings has increased by 5.6%, reflecting improved analyst sentiment and a stronger earnings outlook [4] - Year-to-date, EDU has gained approximately 0%, outperforming the Consumer Discretionary sector average return of -7.9% [4] Industry Context - New Oriental Education is part of the Schools industry, which includes 18 stocks and is currently ranked 20 in the Zacks Industry Rank [6] - The Schools industry has seen a year-to-date gain of about 4.6%, indicating that EDU is slightly underperforming its industry peers [6] Comparative Analysis - Another stock in the Consumer Discretionary sector, H World Group (HTHT), has a year-to-date return of 5.7% and a Zacks Rank of 1 (Strong Buy) [5] - H World Group belongs to the Hotels and Motels industry, which is ranked 159 and has experienced a year-to-date increase of 2.7% [6] Investment Outlook - Investors interested in Consumer Discretionary stocks should monitor both New Oriental Education and H World Group for their continued performance [7]

Group 1 - The report highlights the strong performance of the wind power hydraulic lubrication leader, Chuanrun Co., which is advancing into AIDC liquid cooling, benefiting from the rising industry demand [4] - The company has a solid global layout in high-end energy equipment manufacturing, focusing on offshore wind power and liquid cooling, with overseas revenue reaching 43.64 million yuan in the first half of 2025, a year-on-year increase of 375.7% [4] - The liquid cooling technology is expected to gain traction due to stricter energy consumption regulations for data centers, with NVIDIA's next-generation Rubin chip adopting a fully liquid cooling solution, enhancing market potential [5][6] Group 2 - The asset allocation report emphasizes the continuity of the policy framework for 2026, with a focus on expanding domestic demand and managing financial risks in real estate and local debts [8][9] - The macroeconomic environment is supported by a strong fiscal policy and moderate monetary easing, which is expected to stabilize the equity market [9] - The report outlines a shift towards more execution-oriented industrial policies, enhancing visibility for commercial applications and orders in various sectors [9] Group 3 - The AI demand is projected to exceed expectations, with Shengquan Group positioned to benefit from the high-performance resin market, which is expected to see rapid growth [11] - The company is the largest domestic supplier of electronic chemical materials, with a comprehensive product matrix for high-frequency and high-speed copper-clad laminates [12] - Shengquan Group is expanding its production capacity with new projects set to come online in 2026, including 2000 tons/year of PPO/OPE resin and 1500 tons/year of hydrocarbon resin [12] Group 4 - The automotive industry report discusses the competitive landscape of Robotaxi in the US and China, highlighting Waymo and Tesla as key players in the US market [16][17] - In China, companies like Pony.ai and WeRide are leading the Robotaxi sector, with significant advancements in operational areas and regulatory support for autonomous driving [18] - The report suggests investment opportunities in leading Robotaxi companies and related technologies, emphasizing the acceleration of commercialization in both markets [19] Group 5 - The macroeconomic commentary on the government work report for 2026 outlines a growth target of 4.5%-5%, with a focus on expanding domestic demand and optimizing supply [20][22] - The report emphasizes the importance of employment, with a target of over 12 million new urban jobs, aligning with the economic growth objectives [23] - The fiscal policy remains proactive, with a projected budget expenditure of 30 trillion yuan for 2026, reflecting a commitment to sustainable growth [25][26] Group 6 - The report indicates a strong emphasis on technology innovation as a driver for new economic momentum, with significant increases in R&D investment expected [36][37] - The focus on high-level self-reliance in technology is set to support the development of new industries and enhance the digital economy's contribution to GDP [37][38] - The report outlines plans for substantial investments in modernizing the industrial system, with a focus on high-quality development and technological advancements [38]

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector's performance compared to the overall market [5][10]. Core Insights - The report highlights significant developments in the pharmaceutical sector, including a licensing agreement between China National Pharmaceutical Group (Sinopharm) and Sanofi for the JAK/ROCK inhibitor, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][2]. - Performance forecasts for companies such as Crystal Holding and He Yu indicate substantial revenue growth, with Crystal Holding expected to achieve at least 780 million RMB in revenue for 2025, representing a year-on-year increase of approximately 193% [6][7]. Summary by Sections 1. Overseas Pharmaceuticals - Sinopharm and Sanofi have entered into an exclusive licensing agreement for the global development, production, and commercialization of the JAK/ROCK inhibitor, with potential milestone payments totaling up to 1.395 billion USD [2][7]. - Innovent Biologics' BTK inhibitor, Jiepalit (Pirtobrutinib), has received NMPA approval for a new indication in adult patients with chronic lymphocytic leukemia (CLL) who have previously undergone systemic treatment [2][7]. - Roche's BTK inhibitor Fenebrutinib has successfully met primary endpoints in a Phase III trial for relapsing multiple sclerosis, potentially becoming the first effective oral treatment for both relapsing and primary progressive forms of the disease [3][8]. 2. Performance Updates - Crystal Holding anticipates a revenue of no less than 780 million RMB in 2025, with a net profit of at least 100 million RMB, marking a turnaround from losses [6][7]. - He Yu expects to achieve 612 million RMB in revenue for 2025, reflecting a 21% year-on-year growth, with net profit projected at 55 million RMB, a 95% increase [6][7]. 3. Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [10]. - It also highlights the importance of monitoring clinical progress in key pipelines for companies transitioning towards innovation [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has demonstrated significant improvements in cost control and utilization rates, leading to an upward revision of its full-year revenue guidance [3][6] - For FY2026Q2, the company reported net revenue of $1.19 billion, exceeding the upper limit of its guidance by 2.4%, with a year-over-year growth of 14.7% [6] - The company has increased its full-year revenue forecast to $5.29 billion to $5.49 billion, reflecting a year-over-year growth of 8% to 12% [7][11] Financial Performance - In FY2026Q2, the company achieved a Non-GAAP operating profit of $89.13 million, a year-over-year increase of 206.9%, with a Non-GAAP operating profit margin of 7.5%, up 4.7 percentage points [6] - The company reported a cash and cash equivalents balance of $1.84 billion and deferred revenue of $2.16 billion, indicating robust future business growth [6] - The K12 business segment is expected to drive revenue growth, with a projected growth rate of approximately 20% for FY2026Q3 [8] Revenue and Profit Forecast - The company anticipates FY2026Q3 net revenue between $1.31 billion and $1.35 billion, representing a year-over-year increase of 11% to 14% [7] - Revenue projections for FY2026 to FY2028 are $5.48 billion, $6.11 billion, and $6.77 billion, respectively, with corresponding net profits of $492 million, $600 million, and $694 million [11][13]

Group 1: Industry Investment Rating - The investment rating for the overseas social services industry is positive, with a focus on the record-high visitor numbers during the Macau Spring Festival [6]. Group 2: Core Insights - The total number of inbound visitors to Macau during the Spring Festival reached 1.554 million, with an average daily visitor count of 173,000, marking a year-on-year increase of 5.5% [6][1]. - Among the inbound visitors, mainland tourists averaged 134,000 per day, reflecting a 7% year-on-year growth, while international visitors averaged nearly 7,900 per day, up by 8% [6][1]. - The hotel occupancy rate during the Spring Festival was 95.6%, with the highest rate of 99.2% recorded on the fourth day of the festival [6][1]. Group 3: Summary by Relevant Sections Overseas Pharmaceuticals - The report highlights significant developments in the pharmaceutical sector, including the announcement of clinical trial results for B7-H3 ADC by Yingensheng and the completion of Phase II trials for UBT251 by Lianbang Pharmaceutical [3][10]. - In 2025, BeiGene reported revenues of $5.343 billion, a 40% increase year-on-year, while adjusted net profits reached $917 million, marking a return to profitability [9][21]. - The report also notes that the average weight loss in the UBT251 trial was as high as 19.7% after 24 weeks, compared to a 2.0% loss in the placebo group [11][10]. Overseas Education - The vocational education sector is experiencing an upswing, with promising enrollment data, particularly for China Oriental Education [5][17]. - The education index saw a decline of 4.9% in the recent week, underperforming the Hang Seng National Enterprises Index by 2.1 percentage points [15]. - The report recommends focusing on China Oriental Education, which is expected to see accelerated enrollment growth due to its strategic adjustments in response to market demands [17][15].

Core Viewpoint - Guosen Securities maintains an "outperform" rating for New Oriental-S (09901) and raises the company's net profit forecast for the fiscal years 2026-2028 to $480 million, $560 million, and $620 million respectively, with the latest market capitalization corresponding to PE ratios of 19.5, 17.0, and 15.2 times [1] Group 1: Revenue and Profitability - In FY2026Q2, the company achieved net revenue of $1.191 billion, a year-on-year increase of 14.7%, exceeding market expectations of 12% [1] - The company reported a non-GAAP operating profit of $89.13 million, reflecting a significant increase of 206.9% [1] - Deferred revenue reached $2.162 billion, marking a year-on-year growth of 10.2% [1] Group 2: New Education and Overseas Study Business - The new education business remains a core growth driver, benefiting from an increase in renewal rates, which grew by 21.6% year-on-year, accelerating from 15.3% in FY26Q1 [2] - Non-subject tutoring services covered approximately 1.058 million students, a year-on-year increase of 6.4% [2] - The overseas study-related business showed resilience, with total revenue slightly increasing year-on-year, outperforming previous market expectations of a 5% decline [2] Group 3: Quality Development and Operational Efficiency - As of FY26Q2, the company had 1,379 teaching locations, a 2% increase, continuing its cautious expansion strategy focused on high-quality development [3] - The non-GAAP operating profit margin improved by 4.7 percentage points to 7.5% year-on-year [3] - Gross margin was reported at 53.3%, an increase of 1.3 percentage points, while the management expense ratio remained stable at 31.4% [3] Group 4: Future Outlook - For FY2026Q3, the company expects a year-on-year revenue growth of 11-14% and has raised its full-year revenue growth guidance to 8-12%, up from the previous estimate of 5-10% [4]

Core Viewpoint - Guosen Securities maintains an "outperform" rating for New Oriental-S (09901) and raises the company's net profit forecast for the fiscal years 2026-2028 to $480 million, $560 million, and $620 million, respectively, with the latest market capitalization corresponding to PE ratios of 19.5x, 17.0x, and 15.2x [1] Group 1: Revenue and Profitability - In FY2026Q2, the company achieved net revenue of $1.191 billion, a year-on-year increase of 14.7%, exceeding market expectations of 12% [1] - The company reported a significant increase in operating profit to $89.13 million, up 206.9% year-on-year, indicating continuous improvement in profitability [1] - Deferred revenue reached $2.162 billion, reflecting a year-on-year growth of 10.2% [1] Group 2: New Education and Study Abroad Business - The new education business remains a core growth driver, benefiting from an increase in retention rates, which grew by 21.6% year-on-year, accelerating from 15.3% in FY26Q1 [2] - Non-academic tutoring services reached approximately 1.058 million students, a 6.4% increase, as the company focuses on improving teaching quality and retention rates [2] - The study abroad-related business showed resilience, with total revenue slightly increasing year-on-year, outperforming previous market expectations of a 5% decline [2] Group 3: Quality Development and Operational Efficiency - As of FY26Q2, the company had 1,379 teaching locations, a 2% increase, continuing its cautious expansion strategy focused on high-quality development [3] - The Non-GAAP operating profit margin improved by 4.7 percentage points to 7.5%, with a gross margin of 53.3%, up 1.3 percentage points [3] - The company plans to enhance profitability through organizational optimization and technological advancements [3] Group 4: Future Outlook - For FY2026Q3, the company expects a year-on-year revenue growth of 11-14%, with an upward revision of the full-year revenue growth forecast to 8-12%, previously estimated at 5-10% [3]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4]. Core Insights - The company has adjusted its revenue growth guidance for the fiscal year 2026 to 8-12%, up from the previous estimate of 5-10%, indicating a positive outlook for revenue growth across various business lines [3][21]. - The company reported a significant increase in net revenue of $1.191 billion, representing a year-on-year growth of 14.7%, which exceeded market expectations [2][9]. - The Non-GAAP operating profit reached $89.13 million, showing a remarkable year-on-year increase of 206.9%, reflecting continuous improvement in profitability [2][9]. - Deferred revenue stood at $2.162 billion, marking a 10.2% year-on-year growth, which lays a solid foundation for future revenue recognition [2][9]. Revenue and Business Performance - The new education business remains the core growth driver, with a year-on-year revenue increase of 21.6%, benefiting from improved renewal rates [2][13]. - The number of active paid users for the smart learning system reached 352,000, reflecting a 34.9% year-on-year growth [2][13]. - The company has 1,379 teaching centers, with a cautious expansion strategy, increasing by 2% quarter-on-quarter [3][18]. Financial Projections - The company expects revenue growth of 11-14% for Q3 FY2026, with various segments projected to achieve accelerated growth [3][20]. - The forecast for net profit for the fiscal years 2026-2028 has been raised to $483 million, $555 million, and $620 million, respectively [4][21]. - The latest market capitalization corresponds to a price-to-earnings (PE) ratio of 19.5, 17.0, and 15.2 for the fiscal years 2026, 2027, and 2028 [4][21].